Advertisement

Topics

Selecta Biosciences, Inc. Company Profile

13:27 EDT 27th September 2016 | BioPortfolio

Selecta Biosciences, Inc. is a biopharmaceutical company developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications. Selecta's proprietary Synthetic Vaccine Particle (SVP™) platform creates a new paradigm in vaccine development, enabling completely new therapeutic applications while offering the potential of improved efficacy and safety profiles. Selecta’s fully synthetic engineering of novel vaccines offers a number of compelling benefits, including flexible modular vaccine design and accelerated development timelines using robust manufacturing processes. Selecta’s SVP™ platform technology is flexible to enable diverse vaccines and the company has created targeted antigen-specific Synthetic Vaccine Particles (tSVP™) and targeted antigen-specific tolerogenic Synthetic Vaccine Particles (t2SVP™).


News Articles [753 Associated News Articles listed on BioPortfolio]

Selecta Biosciences files for IPO

Selecta Biosciences Inc. (targeted immunotherapies for serious diseases) filed for its IPO on the NASDAQ. The company closed its Series E round for $38mm in late 2015.

Stifel starts Selecta Biosciences at buy

Stifel launched coverage of Selecta Biosciences (NASDAQ:SELB) with a “buy” rating and $23 price target. The stock closed at $14 on Friday. “Selecta’s SVP-Rapamycin technology has the potential...

Selecta Biosciences Obtains Exclusive License to Proprietary Gene Therapy Vector from Massachusetts Eye and Ear

Thursday, May 19th 2016 at 1:00pm UTC Selecta is licensing Anc80 for a rare genetic disease with options on additional pre-specified indications By combining Anc80 with Selecta’s investigational dru...

Selecta prices $70M IPO

Immunomodulatory company Selecta Biosciences Inc. (NASDAQ:SELB) was unchanged its first day of trading Wednesday after raising $70 million through the sale of 5 million shares at $14 in an IPO. The pr...

Selecta Biosciences nets $65.1mm in IPO

Selecta Biosciences Inc. (targeted immunotherapies for serious diseases) netted $65.1mm in it's IPO of 5mm shares at $14 (bottom of the filing range; deal up-sized from 4.25mm shares at filing). The ...

IPO brings in $70M for Selecta

Selecta Biosciences raised $70 million in an initial public offering.  -More- 

IPO could reel in $64M for Selecta

Watertown, Mass.-based Selecta Biosciences aims to raise $64 million in an initial public offering.  -More- 

Selecta Biosciences raises $70 million in IPO, forges ahead with gout drug

Selecta is the sixth Massachusetts-based biotech to go public this year. 

Drugs and Medications [13 Associated Drugs and Medications listed on BioPortfolio]

Naturally nova scotia hand sanitizer [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Natelle one [Azur Pharma, Inc.]

Natelle OneRx Prenatal Vitamin & Plant-Based DHA Now with 28 mg Iron

Natelle one [Azur Pharma, Inc.]

Natelle®OneRx Prenatal Vitamin & Plant-Based DHA

PubMed Articles [85 Associated PubMed Articles listed on BioPortfolio]

cDNA Library Enrichment of Full Length Transcripts for SMRT Long Read Sequencing.

The utility of genome assemblies does not only rely on the quality of the assembled genome sequence, but also on the quality of the gene annotations. The Pacific Biosciences Iso-Seq technology is a po...

Contents list.

Contents list.

Back cover.

The Grand Challenge of Characterizing Ribonucleoprotein Networks.

Clinical Trials [4 Associated Clinical Trials listed on BioPortfolio]

Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy

The purpose of this research is to determine if a subject's own bone marrow tissue can help regenerate bone in the area of his/her jaw where a tooth has been removed using Tissue Repair Ce...

Identification of Predictive Factors for Survival of Patients With Recurrent Prostate Cancer From Clinical Features, Tissue Image Features and Molecular Biomarker Data

We seek to improve the predictive accuracy of the nomogram to predict survival for patients with castrate mets disease through the addition of pathological data, the results of automated m...

Validation of Decipher Test in African American Men With Prostate Cancer - VANDAAM

The primary purpose of this study is to determine whether a tumor test recently developed by GenomeDx Biosciences known as Decipher® can predict aggressive prostate cancer with the same a...

Validation of Lophius Kits T-Track® CMV and T-Track® EBV in Hemodialysis Patients

Cell-mediated immunity (CMI) and in particular T cells play a critical role in the rejection of transplanted organs. Thus, in transplant recipients a life-long and individualized immunosup...

Companies [326 Associated Companies listed on BioPortfolio]

Selecta Biosciences, Inc.

Selecta Biosciences, Inc. is a biopharmaceutical company developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen...

Selecta Biosciences, Inc. and Genethon

Hydra Biosciences, Inc.

Hydra Biosciences is a privately-held biopharmaceutical company based in Cambridge, Massachusetts, and develops drugs to treat pain, inflammation, anxiety and other diseases using...

Valent BioSciences Corporation

Headquartered in Libertyville, IL, Valent BioSciences is a subsidiary of Tokyo-based Sumitomo Chemical Company and is the worldwide leader in the development, manufacturing and co...

JeNu Biosciences

JeNu Biosciences was founded in 2008 by a team of ultrasound scientists, medical doctors and beauty executives and is currently led by Wayne Wager, CEO. JeNu Biosciences is a Seat...

More Information about "Selecta Biosciences, Inc." on BioPortfolio

We have published hundreds of Selecta Biosciences, Inc. news stories on BioPortfolio along with dozens of Selecta Biosciences, Inc. Clinical Trials and PubMed Articles about Selecta Biosciences, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Selecta Biosciences, Inc. Companies in our database. You can also find out about relevant Selecta Biosciences, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...


Corporate Database Quicklinks



Searches Linking to this Company Record